Avelox Related Published Studies
Well-designed clinical trials related to Avelox (Moxifloxacin)
Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. [2009.09]
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. [2009.08.01]
Electrocardiographic QTc changes due to moxifloxacin infusion. [2009.06]
Pharmacokinetic, pharmacodynamic, and electrocardiographic effects of dapoxetine and moxifloxacin compared with placebo in healthy adult male subjects. [2009.06]
Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested. [2009.05]
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. [2009.04.04]
Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study). [2009.04]
Patients' perception of recovery after third molar surgery following postoperative treatment with moxifloxacin versus amoxicillin and clavulanic acid: a randomized, double-blind, controlled study. [2009.02]
Clinical and microbiological efficacy of moxifloxacin versus amoxicillin/clavulanic acid in severe odontogenic abscesses: a pilot study. [2009.01]
Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial. [2009]
Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection. [2008.12]
Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. [2008.11]
A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis. [2008.11]
The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. [2008.10]
Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery. [2008.09]
Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. [2008.09]
Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial. [2008.05.15]
Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given in different concentrations in a wick before cataract surgery. [2008.05]
A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial. [2008.05]
Ocular Penetration and Pharmacokinetics of Topical Gatifloxacin 0.3% and Moxifloxacin 0.5% Ophthalmic Solutions After Keratoplasty. [2008.04]
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. [2008.03]
Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers. [2008.01]
Ototoxicity of Topical Moxifloxacin in a Chinchilla Animal Model. [2007.12]
Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial. [2007.09]
High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. [2007.06]
The effect of moxifloxacin and gatifloxacin on long-term visual outcomes following photorefractive keratectomy. [2007.04]
Treatment of ankylosing spondylitis with moxifloxacin. [2007.04]
High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. [2007]
Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. [2006.12]
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. [2006.08.01]
Pharmacokinetics of moxifloxacin in rabbits after intravenous, subcutaneous and a long-acting poloxamer 407 gel formulation administration. [2006.08]
Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. [2006.08]
Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients. [2006.04]
Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. [2006.02]
Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. [2006.01.01]
A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. [2005.11]
Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. [2005.11]
Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. [2005.11]
The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomy. [2005.07]
A comparison of therapeutic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK. [2005.06]
Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. [2005.06]
Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. [2005.05.15]
Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. [2005.05]
Penetration of moxifloxacin into the human aqueous humour after oral administration. [2005.05]
Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. [2005.03]
Ocular penetration of moxifloxacin 0.5% and gatifloxacin 0.3% ophthalmic solutions into the aqueous humor following topical administration prior to routine cataract surgery. [2005.01]
Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. [2005]
A comparison of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerability. [2004.11]
Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. [2004.11]
Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis. [2004.09]
Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. [2004.03]
Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. [2004.03]
Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. [2004.03]
Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. [2004.02]
Sinus tissue concentration of moxifloxacin after a single oral dose. [2004.02]
Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. [2004.01]
The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. [2003.12.01]
Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state. [2003.12]
Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. [2003.10]
[A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial] [2003.09]
Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults. [2003.01]
Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). [2002.12]
Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. [2002.06]
A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. [2002.05]
Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. [2002.03]
Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. [2002]
Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin. [2001.12]
A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. [2001.07]
The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. [2001.07]
Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience. [2001.06]
Profile of moxifloxacin drug interactions. [2001.03.15]
Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. [2001.01]
Effect of probenecid on the kinetics of a single oral 400mg dose of moxifloxacin in healthy male volunteers. [2001]
Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers. [2001]
The influence of age and gender on the pharmacokinetics of moxifloxacin. [2001]
Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. [2000.12]
The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. [2000.11]
Impact of moxifloxacin versus clarithromycin on normal oropharyngeal microflora. [2000.07]
A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. [2000.04]
Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. [2000.01]
Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. [1999.11]
Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. [1999.10]
Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Sinusitis Infection Study Group. [1999.10]
Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. [1999.06]
Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. [1999.05]
Fluoroquinolone phototoxicity: a comparison of moxifloxacin and lomefloxacin in normal volunteers. [1999.05]
Absolute bioavailability of moxifloxacin. [1999.03]
Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. [1998.08]
Well-designed clinical trials possibly related to Avelox (Moxifloxacin)
Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis? [2009.08.28]
Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects. [2009.08]
A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. [2009.08]
Comparison of semiautomated and fully automated methods for QT measurement during a thorough QT/QTc study: variability and sample size considerations. [2009.08]
Deferasirox does not induce QT/QTc-prolongation in healthy subjects. [2009.05]
Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study. [2009.03]
Stroke-induced immunodepression and post-stroke infections: lessons from the preventive antibacterial therapy in stroke trial. [2009.02.06]
Corticosteroids for bacterial corneal ulcers. [2009.02]
Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. [2008.12.02]
Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. [2008.12.02]
A comparison of fluoroquinolone penetration into human conjunctival tissue. [2008.12]
Thorough QT/QTc study in patients with advanced parkinson's disease: cardiac safety of rotigotine. [2008.11]
Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. [2008.09]
|
